GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AK Medical Holdings Ltd (HKSE:01789) » Definitions » Peter Lynch Fair Value

AK Medical Holdings (HKSE:01789) Peter Lynch Fair Value : N/A (As of May. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is AK Medical Holdings Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for AK Medical Holdings's Peter Lynch Fair Value or its related term are showing as below:


During the past 10 years, the highest Price to Peter Lynch Fair Value Ratio of AK Medical Holdings was 7.90. The lowest was 1.31. And the median was 2.70.


HKSE:01789's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.685
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


AK Medical Holdings Peter Lynch Fair Value Historical Data

The historical data trend for AK Medical Holdings's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AK Medical Holdings Peter Lynch Fair Value Chart

AK Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.68 8.25 1.74 1.24 -

AK Medical Holdings Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.74 - 1.24 - -

Competitive Comparison of AK Medical Holdings's Peter Lynch Fair Value

For the Medical Devices subindustry, AK Medical Holdings's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AK Medical Holdings's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AK Medical Holdings's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where AK Medical Holdings's Price-to-Peter-Lynch-Fair-Value falls into.



AK Medical Holdings Peter Lynch Fair Value Calculation

AK Medical Holdings's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *0.175
=N/A

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AK Medical Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.18.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


AK Medical Holdings  (HKSE:01789) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

AK Medical Holdings's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=5.43/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AK Medical Holdings Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of AK Medical Holdings's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


AK Medical Holdings (HKSE:01789) Business Description

Traded in Other Exchanges
N/A
Address
No. 10 Baifuquan Road, 2nd Floor, Xingye Mansion, Changping District Science and Technology Park, Beijing, CHN, 102200
AK Medical Holdings Ltd is an investment holding company which designs, develops, produces, and markets orthopedic joint implants and related products. The company's geographical segments include China and the United Kingdom. It derives the majority of revenue from China. The company offers off-the-shelf products, such as knee replacement and hip replacement implants; and 3D-printed products, including 3D-printed hip replacement implants, spinal interbody cages, and artificial vertebral bodies.
Executives
Li Zhijiang
Trident Trust Company (hk) Limited
Ximalaya Limited
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Suntop Limited 2101 Beneficial owner
Zhang Chaoyang 2307 Founder of a discretionary trust who can infl
Bamboo Group Management Limited 2201 Interest of corporation controlled by you
Zhang Bin 2202 Interest of your spouse
Rainbow Holdings Limited 2201 Interest of corporation controlled by you
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Orbimed Advisors Ii Limited
Orbimed Asia Gp Ii, L.p.
Orbimed Asia Partners Ii, L.p.

AK Medical Holdings (HKSE:01789) Headlines

No Headlines